ES2620660T3 - Método para la fabricación de naltrexona - Google Patents
Método para la fabricación de naltrexona Download PDFInfo
- Publication number
- ES2620660T3 ES2620660T3 ES11785301.0T ES11785301T ES2620660T3 ES 2620660 T3 ES2620660 T3 ES 2620660T3 ES 11785301 T ES11785301 T ES 11785301T ES 2620660 T3 ES2620660 T3 ES 2620660T3
- Authority
- ES
- Spain
- Prior art keywords
- naltrexone
- mixture
- noroxymorphone
- pyrrolidone
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003086 naltrexone Drugs 0.000 title abstract description 12
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract description 8
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 abstract description 9
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 abstract description 8
- -1 cyclopropylmethyl halide Chemical class 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41040510P | 2010-11-05 | 2010-11-05 | |
| US410405P | 2010-11-05 | ||
| DK201001007 | 2010-11-05 | ||
| DKPA201001007 | 2010-11-05 | ||
| US201161489701P | 2011-05-25 | 2011-05-25 | |
| DK201100396 | 2011-05-25 | ||
| US201161489701P | 2011-05-25 | ||
| DKPA201100396 | 2011-05-25 | ||
| PCT/DK2011/000128 WO2012059103A1 (en) | 2010-11-05 | 2011-11-04 | Method for the manufacturing of naltrexone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2620660T3 true ES2620660T3 (es) | 2017-06-29 |
Family
ID=45001588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11785301.0T Active ES2620660T3 (es) | 2010-11-05 | 2011-11-04 | Método para la fabricación de naltrexona |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2635586B1 (enExample) |
| JP (2) | JP6246589B2 (enExample) |
| AP (1) | AP3415A (enExample) |
| AU (1) | AU2011325563B2 (enExample) |
| CA (1) | CA2815093C (enExample) |
| CY (1) | CY1118742T1 (enExample) |
| DK (1) | DK2635586T3 (enExample) |
| EA (1) | EA022266B1 (enExample) |
| ES (1) | ES2620660T3 (enExample) |
| HR (1) | HRP20170379T1 (enExample) |
| HU (1) | HUE033596T2 (enExample) |
| LT (1) | LT2635586T (enExample) |
| ME (1) | ME02621B (enExample) |
| MX (1) | MX2013005009A (enExample) |
| PL (1) | PL2635586T3 (enExample) |
| PT (1) | PT2635586T (enExample) |
| RS (1) | RS55777B1 (enExample) |
| SI (1) | SI2635586T1 (enExample) |
| SM (1) | SMT201700177T1 (enExample) |
| WO (1) | WO2012059103A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140005216A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
| AR096851A1 (es) | 2013-07-11 | 2016-02-03 | H Lundbeck As | Sales que no forman hidratos ni solvatos de nalmefeno |
| KR20160093025A (ko) | 2013-12-20 | 2016-08-05 | 하. 룬트벡 아크티에 셀스카브 | 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도 |
| JP6797691B2 (ja) | 2014-04-22 | 2020-12-09 | 大塚製薬株式会社 | ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途 |
| US9701687B2 (en) * | 2014-05-05 | 2017-07-11 | Noramco, Inc. | Process for the preparation of opioid compounds |
| US9701688B2 (en) * | 2014-05-05 | 2017-07-11 | Noramco, Inc. | Process for the preparation of opioid compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535157A (en) | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| US4751307A (en) | 1985-01-17 | 1988-06-14 | Mallinckrodt, Inc. | Wittig-reaction processes |
| ATE178329T1 (de) * | 1989-10-16 | 1999-04-15 | Us Health | Totale synthese von northebain-, normorphin-, noroxymorphon-enantiomeren und -derivaten via n- nor-zwischenverbindungen |
| FR2906252B1 (fr) * | 2006-09-21 | 2008-11-28 | Sanofi Aventis Sa | Procede de preparation d'halogenures de n-aklyl naltrexone |
| WO2008138383A1 (de) | 2007-05-16 | 2008-11-20 | Cilag Ag | Verfahren zur herstellung von n-methylnaltrexonbromid |
| CN102227433B (zh) * | 2008-09-30 | 2015-01-07 | 马林克罗特有限公司 | 烷基化吗啡喃衍生物的仲胺基团的方法 |
| PL2435439T3 (pl) | 2009-05-25 | 2016-05-31 | H Lundbeck As | Wytwarzanie chlorowodorku nalmefenu z naltreksonu |
-
2011
- 2011-11-04 AU AU2011325563A patent/AU2011325563B2/en not_active Ceased
- 2011-11-04 EP EP11785301.0A patent/EP2635586B1/en active Active
- 2011-11-04 JP JP2013537002A patent/JP6246589B2/ja active Active
- 2011-11-04 AP AP2013006897A patent/AP3415A/xx active
- 2011-11-04 HU HUE11785301A patent/HUE033596T2/hu unknown
- 2011-11-04 SM SM20170177T patent/SMT201700177T1/it unknown
- 2011-11-04 CA CA2815093A patent/CA2815093C/en active Active
- 2011-11-04 DK DK11785301.0T patent/DK2635586T3/en active
- 2011-11-04 PL PL11785301T patent/PL2635586T3/pl unknown
- 2011-11-04 HR HRP20170379TT patent/HRP20170379T1/hr unknown
- 2011-11-04 PT PT117853010T patent/PT2635586T/pt unknown
- 2011-11-04 ES ES11785301.0T patent/ES2620660T3/es active Active
- 2011-11-04 RS RS20170244A patent/RS55777B1/sr unknown
- 2011-11-04 MX MX2013005009A patent/MX2013005009A/es active IP Right Grant
- 2011-11-04 SI SI201131131A patent/SI2635586T1/sl unknown
- 2011-11-04 ME MEP-2017-57A patent/ME02621B/me unknown
- 2011-11-04 LT LTEP11785301.0T patent/LT2635586T/lt unknown
- 2011-11-04 WO PCT/DK2011/000128 patent/WO2012059103A1/en not_active Ceased
- 2011-11-04 EA EA201390658A patent/EA022266B1/ru not_active IP Right Cessation
-
2016
- 2016-06-24 JP JP2016125389A patent/JP6215399B2/ja active Active
-
2017
- 2017-03-17 CY CY20171100341T patent/CY1118742T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2635586B1 (en) | 2017-02-08 |
| HUE033596T2 (hu) | 2017-12-28 |
| HRP20170379T1 (hr) | 2017-05-05 |
| JP2016199566A (ja) | 2016-12-01 |
| EA022266B1 (ru) | 2015-11-30 |
| PL2635586T3 (pl) | 2017-06-30 |
| CA2815093A1 (en) | 2012-05-10 |
| AP2013006897A0 (en) | 2013-05-31 |
| MX2013005009A (es) | 2013-08-01 |
| LT2635586T (lt) | 2017-04-10 |
| AP3415A (en) | 2015-09-30 |
| EP2635586A1 (en) | 2013-09-11 |
| JP6246589B2 (ja) | 2017-12-13 |
| PT2635586T (pt) | 2017-03-30 |
| AU2011325563B2 (en) | 2015-08-20 |
| JP2013541564A (ja) | 2013-11-14 |
| JP6215399B2 (ja) | 2017-10-18 |
| RS55777B1 (sr) | 2017-07-31 |
| SI2635586T1 (sl) | 2017-07-31 |
| ME02621B (me) | 2017-06-20 |
| AU2011325563A1 (en) | 2013-05-02 |
| CA2815093C (en) | 2019-08-06 |
| CY1118742T1 (el) | 2017-07-12 |
| EA201390658A1 (ru) | 2013-11-29 |
| WO2012059103A1 (en) | 2012-05-10 |
| SMT201700177T1 (it) | 2017-05-08 |
| DK2635586T3 (en) | 2017-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2620660T3 (es) | Método para la fabricación de naltrexona | |
| ES2585221T3 (es) | Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma | |
| US9255115B2 (en) | Method for producing glufosinate P free acid | |
| GB2542881A8 (en) | Crystal forms of ß-nicotinamide mononucleotide | |
| US20170158682A1 (en) | Method for producing fused heterocyclic compound | |
| PE20110100A1 (es) | Procedimiento de preparacion de n-[trans-4-[4-(ciclopropilmetil)-1-piperazinil]ciclohexil]-4-[[(7r)-7-etil-5,6,7,8-tetrahidro-5-metil-8-(1-metiletil)-6-oxo-2-pteridinil]amino]-3-metoxi-benzamida | |
| MX375073B (es) | Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico. | |
| PH12013500740A1 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same | |
| RU2015108042A (ru) | Способ получения пеметрекседа и его лизиновой соли | |
| CN102408437A (zh) | 一种阿扑西林的制备方法 | |
| AR063415A1 (es) | Hidratos de clorhidrato de erlotinib para el tratamiento del cancer | |
| ES2818736T3 (es) | Método de fluoración aromática | |
| US8318936B2 (en) | Method for producing N-methylnaltrexone bromide | |
| NO338831B1 (no) | Fremgangsmåte for fremstilling av N-substituerte salisylamider | |
| ES2881882T3 (es) | Método para producir ácido N-retinoilaminoalcanosulfónico | |
| RU2016134404A (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
| WO2010089764A3 (en) | Improved process for preparation of nebivolol hydrochloride | |
| BR0215473A (pt) | Sìntese melhorada do intermediário de ceftiofur | |
| EP3112360A1 (en) | Process for the preparation of efinaconazole | |
| CA2800345A1 (en) | Process for the preparation of the compound osi - 9 06 | |
| US8362269B2 (en) | Preparation of 1,7′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole | |
| WO2012076736A1 (es) | Fenucil deuterado y derivados, procedimiento para su preparación y usos de los mismos | |
| EP2081920A4 (en) | PROCESS FOR PREPARING CRYSTALLINE 3-O-ALKYLASCORBIC ACID | |
| CN104447776A (zh) | 一种新型杂环有机化合物及其制备方法 | |
| RU2537361C1 (ru) | Оптические изомеры (+) и (-)-бензгидрилмочевин и (+) и (-)-1-[(3-хлорфенил)-фенил-метил]мочевины, фармацевтическая композиция на их основе и способ их получения |